Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dabigatran vs. rivaroxaban-Boehringer Ingelheim-atrial fibrillation
- Development stage
- Approved
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
dabigatran vs. rivaroxaban-Boehringer Ingelheim-atrial fibrillation refers to a retrospective observational study, supported by Boehringer Ingelheim, that compared the safety and effectiveness of three direct oral anticoagulants (DOACs): dabigatran (Pradaxa), rivaroxaban (Xarelto), and apixaban (Eliquis). The study utilized real-world data from the US Department of Defense (DoD) Military Health System to evaluate treatment-naive patients with non-valvular atrial fibrillation (NVAF). Dabigatran is a small molecule direct thrombin inhibitor (Factor IIa), while rivaroxaban and apixaban are small molecule Factor Xa inhibitors. All three agents are indicated for the reduction of stroke and systemic embolism risk in patients with NVAF. The research focused on comparing the incidence of thromboembolic events and major bleeding complications among these standard-dose anticoagulants in clinical practice.
- Brand names
- PradaxaXareltoEliquis
- Other names
- Dabigatran vs. RivaroxabanDabigatran vs. ApixabanSafety and Effectiveness Study Comparing Dabigatran, Rivaroxaban & Apixaban in Non-valvular Atrial Fibrillation Patients Enrolled in the US Department of Defense Military Health System
02
Targets
F10 (Factor Xa)F2 (Thrombin)
Beyond the preview
Go deeper on dabigatran vs. rivaroxaban-Boehringer Ingelheim-atrial fibrillation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dabigatran vs. rivaroxaban-Boehringer Ingelheim-atrial fibrillation.